StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) stock

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30178% above fair value
$26.63−0.05 (-0.19%)

Close on Nov 16, 2026Market cap $1.72BP/E –Yield –

Stoke Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Stoke Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $168.57M, up 61.8% year over year. For fiscal 2025 it was $137.92M, up 54.7% from the year before. The highest annual figure on record is $137.92M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$137.92M+54.7%
FY2024Dec 31, 2024$89.13M+8.4%
FY2023Dec 31, 2023$82.23M+5.6%
FY2022Dec 31, 2022$77.84M+43.7%
FY2021Dec 31, 2021$54.17M+68.2%
FY2020Dec 31, 2020$32.20M+35.5%
FY2019Dec 31, 2019$23.76M+183.9%
FY2018Dec 31, 2018$8.37M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$49.50M+91.5%
Q1 FY2026Mar 31, 2026$39.67M+21.4%
Q4 FY2025Dec 31, 2025$41.70M+78.0%
Q3 FY2025Sep 30, 2025$37.70M+69.8%
Q2 FY2025Jun 30, 2025$25.86M+22.3%
Q1 FY2025Mar 31, 2025$32.68M+46.1%
Q4 FY2024Dec 31, 2024$23.42M+7.6%
Q3 FY2024Sep 30, 2024$22.21M+9.5%
Q2 FY2024Jun 30, 2024$21.14M+2.8%
Q1 FY2024Mar 31, 2024$22.37M+13.9%
Q4 FY2023Dec 31, 2023$21.78M+3.4%
Q3 FY2023Sep 30, 2023$20.27M+0.8%
Q2 FY2023Jun 30, 2023$20.55M+11.9%
Q1 FY2023Mar 31, 2023$19.63M+7.2%
Q4 FY2022Dec 31, 2022$21.06M+33.3%
Q3 FY2022Sep 30, 2022$20.11M+40.1%
Q2 FY2022Jun 30, 2022$18.36M+30.2%
Q1 FY2022Mar 31, 2022$18.31M+84.7%
Q4 FY2021Dec 31, 2021$15.80M+77.5%
Q3 FY2021Sep 30, 2021$14.36M+77.1%
Q2 FY2021Jun 30, 2021$14.10M+76.9%
Q1 FY2021Mar 31, 2021$9.91M+37.4%
Q4 FY2020Dec 31, 2020$8.90M+25.6%
Q3 FY2020Sep 30, 2020$8.11M+24.4%
Q2 FY2020Jun 30, 2020$7.97M+32.3%
Q1 FY2020Mar 31, 2020$7.22M+74.6%
Q4 FY2019Dec 31, 2019$7.09M+136.0%
Q3 FY2019Sep 30, 2019$6.52M+192.7%
Q2 FY2019Jun 30, 2019$6.02M+219.0%
Q1 FY2019Mar 31, 2019$4.13M–
Q4 FY2018Dec 31, 2018$3.00M–
Q3 FY2018Sep 30, 2018$2.23M–
Q2 FY2018Jun 30, 2018$1.89M–

More Stoke Therapeutics figures

See a number that looks wrong?